{
    "1": {
        "question": "What percentage of post-Covid syndrome (PCS) patients reported no response to SSRIs in this study?",
        "options": {
            "A": "5%",
            "B": "10%",
            "C": "15%",
            "D": "20%",
            "E": "25%",
            "F": "I don't know"
        }
    },
    "2": {
        "question": "According to the article, what is the hypothesized primary biochemical pathway disrupted in PCS?",
        "options": {
            "A": "Serotonin pathway",
            "B": "Dopamine pathway",
            "C": "Kynurenine pathway",
            "D": "Glutamate pathway",
            "E": "Cortisol pathway",
            "F": "I don't know"
        }
    },
    "3": {
        "question": "Which SSRI was recommended preferentially due to its sigma1 receptor agonist properties?",
        "options": {
            "A": "Sertraline",
            "B": "Paroxetine",
            "C": "Citalopram",
            "D": "Venlafaxine",
            "E": "Quetiapine",
            "F": "I don't know"
        }
    },
    "4": {
        "question": "What was the mean Bell score reported by patients during PCS before starting SSRI treatment?",
        "options": {
            "A": "15.5",
            "B": "23.5",
            "C": "35.0",
            "D": "47.2",
            "E": "50.0",
            "F": "I don't know"
        }
    },
    "5": {
        "question": "What symptom showed the greatest decrease after SSRI treatment according to the article?",
        "options": {
            "A": "Headache",
            "B": "Muscle pain",
            "C": "Dysautonomia",
            "D": "Brainfog",
            "E": "Palpitations",
            "F": "I don't know"
        }
    },
    "6": {
        "question": "Which of the following neurotransmitter pathways did SSRIs not directly aim to modulate in the study?",
        "options": {
            "A": "Serotonin",
            "B": "Glutamate",
            "C": "Dopamine",
            "D": "GABA",
            "E": "Norepinephrine",
            "F": "I don't know"
        }
    },
    "7": {
        "question": "According to the article, why might SSRIs reduce brainstem disruptions?",
        "options": {
            "A": "By increasing acetylcholine",
            "B": "By modulating cytokine levels",
            "C": "By enhancing glicogen synthesis",
            "D": "By increasing the density of serotonin receptors",
            "E": "By increasing melatonin production",
            "F": "I don't know"
        }
    },
    "8": {
        "question": "What percentage of patients reported dissociative symptoms that disappeared after SSRI treatment?",
        "options": {
            "A": "15%",
            "B": "25%",
            "C": "35%",
            "D": "45%",
            "E": "55%",
            "F": "I don't know"
        }
    },
    "9": {
        "question": "What metodological limitation does the study acknowledge regarding its experimental design?",
        "options": {
            "A": "Involvement of children",
            "B": "Use of unvalidated questionnaires",
            "C": "Lack of a control group",
            "D": "Short duration of treatment",
            "E": "Exclusion of non-Dutch citizens",
            "F": "I don't know"
        }
    },
    "10": {
        "question": "Which of the following demographics was significantly overrepresented in the study sample?",
        "options": {
            "A": "Males with diabetes",
            "B": "Females without children",
            "C": "Males with autoimmunity",
            "D": "Females in healthcare and education",
            "E": "Individuals over 65",
            "F": "I don't know"
        }
    },
    "11": {
        "question": "What was the average improvement in Bell score after SSRI treatment?",
        "options": {
            "A": "20 points",
            "B": "23.7 points",
            "C": "30 points",
            "D": "40 points",
            "E": "50 points",
            "F": "I don't know"
        }
    },
    "12": {
        "question": "How was the potential involvement of the kynurenine pathway assessed in the study?",
        "options": {
            "A": "Through PET scans",
            "B": "By measuring metabolites",
            "C": "Through genetic testing",
            "D": "By hormonal analysis",
            "E": "Through neuropsychological assessments",
            "F": "I don't know"
        }
    },
    "13": {
        "question": "How many patients reported improved sleep after starting SSRIs?",
        "options": {
            "A": "25",
            "B": "29",
            "C": "35",
            "D": "40",
            "E": "50",
            "F": "I don't know"
        }
    },
    "14": {
        "question": "Which SSRI is also a SNRI and was recommended in the study?",
        "options": {
            "A": "Sertraline",
            "B": "Fluoxetine",
            "C": "Venlafaxine",
            "D": "Escitalopram",
            "E": "Paroxetine",
            "F": "I don't know"
        }
    },
    "15": {
        "question": "Which symptom did not show significant improvement after SSRI treatment as per the study?",
        "options": {
            "A": "Brainfog",
            "B": "Chronic fatigue",
            "C": "Muscle pain",
            "D": "Overstimulation",
            "E": "Tinnitus",
            "F": "I don't know"
        }
    },
    "16": {
        "question": "According to the study, what might be a reason that women have more severe PCS symptoms?",
        "options": {
            "A": "Hormonal differences",
            "B": "More active lifestyle",
            "C": "Immune-related genes on the X chromosome",
            "D": "Higher likelihood of working in healthcare",
            "E": "Onset of menopause",
            "F": "I don't know"
        }
    },
    "17": {
        "question": "Which SSRI had the lowest average dosage according to Table 1?",
        "options": {
            "A": "Citalopram",
            "B": "Fluvoxamine",
            "C": "Venlafaxine",
            "D": "Escitalopram",
            "E": "Fluoxetine",
            "F": "I don't know"
        }
    },
    "18": {
        "question": "What correlation was found between the Bell score improvements and open question outcomes?",
        "options": {
            "A": "Negative correlation",
            "B": "No correlation",
            "C": "Moderate correlation",
            "D": "Strong negative correlation",
            "E": "Strong positive correlation",
            "F": "I don't know"
        }
    },
    "19": {
        "question": "Which effect measurement tool was used to measure functional ability?",
        "options": {
            "A": "Chalder Fatigue Scale",
            "B": "Canadian Consensus Criteria",
            "C": "Bell\u2019s Functionality Score",
            "D": "General Anxiety Disorder Scale",
            "E": "Hamilton Depression Rating Scale",
            "F": "I don't know"
        }
    },
    "20": {
        "question": "Which neurotransmitter is directly associated with SSRI functioning mentioned in the article?",
        "options": {
            "A": "GABA",
            "B": "Noradrenaline",
            "C": "Serotonin",
            "D": "Acetylcholine",
            "E": "Melatonin",
            "F": "I don't know"
        }
    },
    "21": {
        "question": "In the study, which patient group showed the least response to SSRIs?",
        "options": {
            "A": "Patients with ME/CFS",
            "B": "Patients with fibromyalgia",
            "C": "Patients with ADHD",
            "D": "Patients with depression",
            "E": "Patients with chronic fatigue",
            "F": "I don't know"
        }
    },
    "22": {
        "question": "What was the reported average duration of PCS among study participants before starting SSRI treatment?",
        "options": {
            "A": "10 months",
            "B": "12 months",
            "C": "15 months",
            "D": "18 months",
            "E": "20 months",
            "F": "I don't know"
        }
    },
    "23": {
        "question": "Which of the following serotoninergic system locations was highlighted in the study related to SSRIs?",
        "options": {
            "A": "Hypothalamus",
            "B": "Cortex",
            "C": "Pons",
            "D": "Spinal cord",
            "E": "Medulla oblongata",
            "F": "I don't know"
        }
    },
    "24": {
        "question": "Which SSRI was least used in the study according to Table 1?",
        "options": {
            "A": "Citalopram",
            "B": "Fluvoxamine",
            "C": "Venlafaxine",
            "D": "Escitalopram",
            "E": "Paroxetine",
            "F": "I don't know"
        }
    },
    "25": {
        "question": "What were the completion criteria for part B of the questionnaire?",
        "options": {
            "A": "At least 2 weeks after starting SSRI treatment",
            "B": "At least 6 weeks after starting SSRI treatment",
            "C": "At least 4 to 6 weeks after starting SSRI treatment",
            "D": "At least 1 week after starting SSRI treatment",
            "E": "Immediately after starting SSRI treatment",
            "F": "I don't know"
        }
    },
    "26": {
        "question": "Which complaint correlated most strongly with overall symptom improvement?",
        "options": {
            "A": "Headache",
            "B": "Dyspnoea",
            "C": "Brainfog",
            "D": "Muscle weakness",
            "E": "Palpitations",
            "F": "I don't know"
        }
    },
    "27": {
        "question": "What was identified as a possible risk factor for PCS in this study?",
        "options": {
            "A": "Dietary habits",
            "B": "Factor V Leiden thrombophilia",
            "C": "Living in urban areas",
            "D": "Low socioeconomic status",
            "E": "High sodium intake",
            "F": "I don't know"
        }
    },
    "28": {
        "question": "Which effect measurement showed the highest reliability in evaluating treatment outcomes?",
        "options": {
            "A": "Open Question Outcomes",
            "B": "Scoring List",
            "C": "Bell Score",
            "D": "Chalder Fatigue Scale",
            "E": "None",
            "F": "I don't know"
        }
    },
    "29": {
        "question": "Which alternative medication was recommended for sleep disturbances instead of mirtazapine?",
        "options": {
            "A": "Melatonin",
            "B": "Promethazine syrup",
            "C": "Lorazepam",
            "D": "Gabapentin",
            "E": "Trazodone",
            "F": "I don't know"
        }
    },
    "30": {
        "question": "Findings related to which receptor suggest additional anti-inflammatory effects from some SSRIs?",
        "options": {
            "A": "Sigma1 receptor",
            "B": "Dopamine receptor",
            "C": "Muscarinic receptor",
            "D": "Histamine receptor",
            "E": "NMDA receptor",
            "F": "I don't know"
        }
    },
    "31": {
        "question": "In Table 2, which group expressed the least evidence of differences in outcomes due to SSRIs?",
        "options": {
            "A": "Age",
            "B": "Gender",
            "C": "Hospitalization during COVID",
            "D": "Asthma/Allergies",
            "E": "Auto-immune diseases",
            "F": "I don't know"
        }
    },
    "32": {
        "question": "Which statement about the Bell's Functionality Score is true according to the article?",
        "options": {
            "A": "It measures only cognitive impairments",
            "B": "It is scored out of 100 points",
            "C": "It lacks evidence for PCS settings",
            "D": "It is a self-administered test completed weekly",
            "E": "It is specific to anxiety disorder assessments",
            "F": "I don't know"
        }
    },
    "33": {
        "question": "What underlying theoretical mechanism could explain SSRIs' potential to benefit blood circulation in PCS?",
        "options": {
            "A": "Reduction in muscle contractions",
            "B": "Increase in serotonin mobilization",
            "C": "Anti-inflammatory effects on endothelial cells",
            "D": "Lipid metabolism regulation",
            "E": "Enhanced oxygenation",
            "F": "I don't know"
        }
    },
    "34": {
        "question": "What type of psychological disorder did at least four patients develop during PCS highlighting SSRIs' effects?",
        "options": {
            "A": "Personality disorder",
            "B": "Bipolar disorder",
            "C": "Obsessive-compulsive disorder",
            "D": "Clinical depression or anxiety disorder",
            "E": "Attention deficit disorder",
            "F": "I don't know"
        }
    },
    "35": {
        "question": "What role does Nicotinic Acid adenine dinucleotide (NAD\u207a) play in the study\u2019s hypothesized SSC\u2019s action?",
        "options": {
            "A": "It acts as a serotonin receptor",
            "B": "It is an energy cofactor via the KP",
            "C": "It inhibits the tryptophan pathway",
            "D": "It regulates cortisol release",
            "E": "It acts as a neurotransmitter",
            "F": "I don't know"
        }
    },
    "36": {
        "question": "What was the common medical advice given to PCS patients before starting SSRI treatment regarding vitamin status?",
        "options": {
            "A": "Ensure adequate vitamin A levels",
            "B": "Test and complement vitamin D and B12 if necessary",
            "C": "Initiate a vitamin C supplementation routine",
            "D": "Assess vitamin E levels",
            "E": "Include a multivitamin",
            "F": "I don't know"
        }
    },
    "37": {
        "question": "How did the article suggest the brainstem might be involved in the therapeutic effects of SSRIs?",
        "options": {
            "A": "Through reduction of serotonin inactivation",
            "B": "By acting primarily in the pineal gland",
            "C": "By directly stimulating the hippocampus",
            "D": "By improving sleep via melatonin production",
            "E": "By altering taste and movement sensation",
            "F": "I don't know"
        }
    },
    "38": {
        "question": "What is one potential reason for the observed gender distribution skewness among PCS patients?",
        "options": {
            "A": "Greater exposure to environmental toxins",
            "B": "Lower baseline immunity in females",
            "C": "Genes for the immune system are on the X chromosome",
            "D": "Higher rates of vitamin D deficiency in males",
            "E": "Women receive less effective treatments",
            "F": "I don't know"
        }
    },
    "39": {
        "question": "What percentage of patients initially experienced severe side effects with SSRIs in this study?",
        "options": {
            "A": "55.7%",
            "B": "13.7%",
            "C": "9.5%",
            "D": "31.6%",
            "E": "71.0%",
            "F": "I don't know"
        }
    },
    "40": {
        "question": "Which supportive evidence is mentioned for SSRIs\u2019 positive effect being more than a placebo?",
        "options": {
            "A": "Insurance covering the cost of SSRIs",
            "B": "Patients' social conditions pre-PCS",
            "C": "Positive effects persisting after 6 months",
            "D": "Rapid response within the first few days",
            "E": "Multi-cross-sectional population studies",
            "F": "I don't know"
        }
    },
    "41": {
        "question": "Which neurobiological mechanism was NOT supported by clinical evidence in this study?",
        "options": {
            "A": "HPA axis",
            "B": "Brain stem",
            "C": "CNS involvement",
            "D": "ADT tolerance",
            "E": "Circulatory system",
            "F": "I don't know"
        }
    },
    "42": {
        "question": "Which symptom associated with PCS had nearly universal scoring in the 'Open Question Outcomes'?",
        "options": {
            "A": "Muscle pain",
            "B": "Dyspnoea",
            "C": "Post-exertional malaise (PEM)",
            "D": "Dysautonomia",
            "E": "Chronic fatigue",
            "F": "I don't know"
        }
    },
    "43": {
        "question": "What association has been observed between kynurenine levels and cognitive impairment in PCS?",
        "options": {
            "A": "Inverse association",
            "B": "Positive association",
            "C": "No Association",
            "D": "Random fluctuations",
            "E": "Negative trend",
            "F": "I don't know"
        }
    },
    "44": {
        "question": "Why might SSRIs take longer to show full effect in the study\u2019s population?",
        "options": {
            "A": "Delayed absorption in the digestive tract",
            "B": "The extended metabolic rate of SSRIs",
            "C": "The time needed for neurotransmitter system resetting",
            "D": "Negative interactions with other medications",
            "E": "Initial under-dosage of SSRIs",
            "F": "I don't know"
        }
    },
    "45": {
        "question": "Why are overactive kynurenine pathways problematic in PCS patients?",
        "options": {
            "A": "They improve viral load management",
            "B": "They increase energy cofactor production",
            "C": "They maintain inflammation and reduce tryptophan",
            "D": "They inhibit immunological synapses",
            "E": "They enhance serotonin release",
            "F": "I don't know"
        }
    },
    "46": {
        "question": "What unique form of measurement did the researchers rely on heavily in this study?",
        "options": {
            "A": "PET/MRI imaging",
            "B": "Open-ended questionnaire outcomes",
            "C": "Blood biomarker analysis",
            "D": "Clinical interviews",
            "E": "Mobile health apps",
            "F": "I don't know"
        }
    },
    "47": {
        "question": "In which symptomatic area did patients experience the least improvement with SSRI treatment?",
        "options": {
            "A": "Fatigue reductions",
            "B": "Brainfog clarity",
            "C": "Muscle pain reduction",
            "D": "Stress adaptations",
            "E": "Chewing ability",
            "F": "I don't know"
        }
    },
    "48": {
        "question": "Which neurotransmitter system was highlighted as maintaining muscle weakness in PCS due to autoantibodies?",
        "options": {
            "A": "GABA",
            "B": "Dopamine",
            "C": "Norepinephrine",
            "D": "Acetylcholine",
            "E": "Serotonin",
            "F": "I don't know"
        }
    },
    "49": {
        "question": "What cardiovascular impact might SSRIs have according to the article?",
        "options": {
            "A": "Enhanced heart rate",
            "B": "Increased blood clot formation",
            "C": "Improved circulation via endothelial effects",
            "D": "Accelerated hardening of arteries",
            "E": "Suppressed respiration rates",
            "F": "I don't know"
        }
    },
    "50": {
        "question": "How many independent researchers were involved in evaluating the Open Question Outcomes?",
        "options": {
            "A": "1",
            "B": "2",
            "C": "3",
            "D": "4",
            "E": "5",
            "F": "I don't know"
        }
    }
}